{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:09:19Z","timestamp":1788592159415,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI Grant","award":["JP 24K19673"],"award-info":[{"award-number":["JP 24K19673"]}]},{"name":"Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake","award":["Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake"],"award-info":[{"award-number":["Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake"]}]},{"name":"Japanese Urological Association Young Researcher Promotion Grant","award":["Japanese Urological Association Young Researcher Promotion Grant"],"award-info":[{"award-number":["Japanese Urological Association Young Researcher Promotion Grant"]}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","award":["Kobayashi Foundation for Cancer Research"],"award-info":[{"award-number":["Kobayashi Foundation for Cancer Research"]}],"id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["Takeda Science Foundation"],"award-info":[{"award-number":["Takeda Science Foundation"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00259-024-06945-x","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T03:16:38Z","timestamp":1728702998000},"page":"469-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model"],"prefix":"10.1007","volume":"52","author":[{"given":"Kei","family":"Yaginuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Joho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Ukon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunta","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Onagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"6945_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"6945_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76\u201385.","journal-title":"Nat Clin Pract Urol"},{"key":"6945_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"6945_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, castration-sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"6945_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"6945_CR6","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med. 2015;373:1697\u2013708.","journal-title":"N Engl J Med"},{"key":"6945_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate Cancer therapies: management of metastatic castration-resistant prostate Cancer in the era of Precision Oncology. Eur Urol. 2019;75:88\u201399.","journal-title":"Eur Urol"},{"key":"6945_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate Cancer. N Engl J Med. 2018;378:645\u201357.","journal-title":"N Engl J Med"},{"key":"6945_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"6945_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","volume":"46","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and Radionuclide Therapy in prostate Cancer. Semin Nucl Med. 2016;46:522\u201335.","journal-title":"Semin Nucl Med"},{"key":"6945_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","volume":"42","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Bene\u0161ov\u00e1 M, Mier W, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6945_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"6945_CR13","doi-asserted-by":"crossref","first-page":"13N","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"FDA Approves Pluvicto","year":"2022","unstructured":"FDA Approves Pluvicto. Locametz for metastatic castration-resistant prostate Cancer. J Nucl Med. 2022;63:13\u00a0N.","journal-title":"J Nucl Med"},{"key":"6945_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and Meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"6945_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","volume":"58","author":"U Haberkorn","year":"2017","unstructured":"Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of Radioligand Therapy: \u03b1, \u03b2, or both? J Nucl Med. 2017;58:1017\u20138.","journal-title":"J Nucl Med"},{"key":"6945_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-resistant prostate Cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"6945_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Weichert W, Haberkorn U, et al. Targeted \u03b1-Therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624\u201331.","journal-title":"J Nucl Med"},{"key":"6945_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"6945_CR19","doi-asserted-by":"publisher","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","volume":"123","author":"KA Morgan","year":"2023","unstructured":"Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64\/67, Actinium-225, and Lead-212\/203 radionuclides. Chem Rev. 2023;123:12004\u201335.","journal-title":"Chem Rev"},{"key":"6945_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph8020321","volume":"8","author":"RM De Kruijff","year":"2015","unstructured":"De Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha Radionuclide Therapy\u2014How to Deal with recoiling daughters? Pharmaceuticals. 2015;8:321\u201336.","journal-title":"Pharmaceuticals"},{"key":"6945_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","volume":"63","author":"RC Mease","year":"2022","unstructured":"Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, et al. An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy. J Nucl Med. 2022;63:259\u201367.","journal-title":"J Nucl Med"},{"key":"6945_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.nucmedbio.2007.03.007","volume":"34","author":"MR Zalutsky","year":"2007","unstructured":"Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779\u201385.","journal-title":"Nucl Med Biol"},{"key":"6945_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1874471011104030177","volume":"4","author":"MR Zalutsky","year":"2011","unstructured":"Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011;4:177\u201385.","journal-title":"Curr Radiopharm"},{"key":"6945_CR24","first-page":"591","volume":"21","author":"C Lundh","year":"2006","unstructured":"Lundh C, Lindencrona U, Schmitt A, Nilsson M, Forssell-Aronsson E. Biodistribution of Free 211At and 125I\u2013 in Nude mice bearing tumours derived from anaplastic thyroid carcinoma cell lines. Cancer Biother Radiopharm. 2006;21:591\u2013600.","journal-title":"Cancer Biother Radiopharm"},{"key":"6945_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40658-020-00326-7","volume":"7","author":"N Ukon","year":"2020","unstructured":"Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S, et al. Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Phys. 2020;7:58.","journal-title":"EJNMMI Phys"},{"key":"6945_CR26","first-page":"425","volume":"35","author":"S Lindegren","year":"2020","unstructured":"Lindegren S, Albertsson P, B\u00e4ck T, Jensen H, Palm S, Aneheim E. Realizing clinical trials with Astatine-211: the Chemistry infrastructure. Cancer Biother Radiopharm. 2020;35:425\u201336.","journal-title":"Cancer Biother Radiopharm"},{"key":"6945_CR27","doi-asserted-by":"publisher","first-page":"15846","DOI":"10.1021\/acs.jmedchem.1c01147","volume":"64","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Kaizuka Y, Tatsuta M, Tanaka H, Washiya N, Shirakami Y, et al. Neopentyl Glycol as a Scaffold to provide Radiohalogenated Theranostic pairs of high in vivo Stability. J Med Chem. 2021;64:15846\u201357.","journal-title":"J Med Chem"},{"key":"6945_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for prostate Cancer imaging. J Nucl Med. 2017;58:425\u201331.","journal-title":"J Nucl Med"},{"key":"6945_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s41181-024-00278-8","volume":"9","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Kannaka K, Hirayama M, Yamashita T, Kaizuka Y, Kobayashi R, et al. In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure. EJNMMI Radiopharm Chem. 2024;9:48.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"6945_CR30","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.7150\/thno.68715","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Sun R, Wang J, Li J, Walker E, Shirke A, et al. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer. Theranostics. 2022;12:2335\u201350.","journal-title":"Theranostics"},{"key":"6945_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/pros.22789","volume":"74","author":"SS Huang","year":"2014","unstructured":"Huang SS, Wang X, Zhang Y, Doke A, DiFilippo FP, Heston WD. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker. Prostate. 2014;74:702\u201313.","journal-title":"Prostate"},{"key":"6945_CR32","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","volume":"57","author":"AP Kiess","year":"2016","unstructured":"Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted \u03b1-Particle Radiopharmaceutical Therapy. J Nucl Med. 2016;57:1569\u201375.","journal-title":"J Nucl Med"},{"key":"6945_CR33","unstructured":"iMAGINE-X: The world\u02bcs highest-class high-resolution X-ray and gamma ray imaging technologies [Internet]. iMAGINE-X: The world\u02bcs highest-class high-resolution X-ray and gamma ray imaging technologies. [cited 2024 Jul 9]. https:\/\/imagine-x.jp\/en\/"},{"key":"6945_CR34","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1681\/ASN.2004110945","volume":"16","author":"JS Jaggi","year":"2005","unstructured":"Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with \u03b1-Particle\u2013emitting actinium daughters. J Am Soc Nephrol. 2005;16:2677.","journal-title":"J Am Soc Nephrol"},{"key":"6945_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/HP.0000000000000935","volume":"116","author":"GA Parker","year":"2019","unstructured":"Parker GA, Cohen EP, Li N, Takayama K, Farese AM, MacVittie TJ. Radiation Nephropathy in a Nonhuman Primate Model of partial-body irradiation with minimal bone marrow sparing-part 2: histopathology, mediators, and mechanisms. Health Phys. 2019;116:409\u201325.","journal-title":"Health Phys"},{"key":"6945_CR36","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"6945_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","volume":"50","author":"T Watabe","year":"2022","unstructured":"Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, et al. Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging. 2022;50:849\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6945_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, Priv\u00e9 BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49:460\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6945_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.114.147181","volume":"56","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293\u20138.","journal-title":"J Nucl Med"},{"key":"6945_CR40","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"6945_CR41","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.3390\/cancers14225651","volume":"14","author":"SD Busslinger","year":"2022","unstructured":"Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, M\u00fcller C. [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers (Basel). 2022;14:5651.","journal-title":"Cancers (Basel)"},{"key":"6945_CR42","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acs.jmedchem.1c00117","volume":"64","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wu Y, Zeng Q, Xie T, Yao S, Zhang J, et al. Synthesis, preclinical evaluation, and first-in-human PET study of Quinoline-Containing PSMA tracers with decreased renal excretion. J Med Chem. 2021;64:4179\u201395.","journal-title":"J Med Chem"},{"key":"6945_CR43","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","volume":"60","author":"NJ Rupp","year":"2019","unstructured":"Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, T\u00f6pfer A, M\u00fcller J, et al. First clinicopathologic evidence of a Non-PSMA-Related uptake mechanism for 68Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60:1270\u20136.","journal-title":"J Nucl Med"},{"key":"6945_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant prostate Cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350.","journal-title":"Eur Urol"},{"key":"6945_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","volume":"59","author":"T Langbein","year":"2018","unstructured":"Langbein T, Chauss\u00e9 G, Baum RP. Salivary gland toxicity of PSMA Radioligand Therapy: relevance and preventive strategies. J Nucl Med. 2018;59:1172\u20133.","journal-title":"J Nucl Med"},{"key":"6945_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.118.212720","volume":"60","author":"M Schottelius","year":"2019","unstructured":"Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, et al. Synthesis and preclinical characterization of the PSMA-Targeted hybrid Tracer PSMA-I&F for nuclear and fluorescence imaging of prostate Cancer. J Nucl Med. 2019;60:71\u20138.","journal-title":"J Nucl Med"},{"key":"6945_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2967\/jnumed.116.178939","volume":"58","author":"S Robu","year":"2017","unstructured":"Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided surgery in prostate Cancer. J Nucl Med. 2017;58:235\u201342.","journal-title":"J Nucl Med"},{"key":"6945_CR48","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a function of Cellular PSMA levels and Intratumoural PSMA HeterogeneityPSMA-RLT efficacy as function of PSMA Level and Heterogeneity. Clin Cancer Res. 2020;26:2946\u201355.","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T20:51:54Z","timestamp":1736887914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6945"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06945-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were conducted in accordance with the institutional guidelines approved by the Fukushima Medical University School of Medicine Institute of Animal Care and Use Committee (approval number: 2024-046).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}